.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Multiple myeloma remains a significant challenge in hematology due to persistent drug resistance and an immunosuppressive bone marrow microenvironment. Oncolytic virotherapy for myeloma has emerged as a dual-action approach that combines direct tumor cell lysis with robust immune activation. While human viruses often face hurdles from pre-existing immunity, researchers are now looking toward non-pathogenic animal viruses like bovine herpesvirus type 1 (BoHV-1). This virus selectively infects malignant plasma cells, triggering a cascade of anti-tumor events that could redefine standard care protocols.
BoHV-1 effectively enters myeloma cells and induces mitochondrial apoptosis. This process suppresses critical pro-survival programs, such as MYC targets and oxidative phosphorylation. Notably, the infection alters the cell surface by upregulating natural killer (NK)-activating ligands while simultaneously downregulating MHC class I molecules. Consequently, malignant cells become far more susceptible to NK-mediated cytotoxicity. In patient-derived samples, the virus selectively targets malignant cells and immunosuppressive myeloid subsets while leaving healthy hematopoietic progenitors unharmed.
A major breakthrough in this research involves the oncolytic virotherapy for myeloma induced shift toward a pro-inflammatory state. The virus promotes the activation of CD8+ T cells and drives monocytes toward an M1-like polarization. This immune remodeling triggers an inflammatory cytokine storm characterized by high levels of type I and II interferons. Furthermore, BoHV-1 upregulates CD38 expression on both myeloma and immune effector cells. This specific change significantly enhances the sensitivity of tumor cells to the monoclonal antibody daratumumab, offering a potent synergistic effect.
Combining BoHV-1 with established therapies like bortezomib or lenalidomide further increases anti-myeloma cytotoxicity. These findings suggest that BoHV-1 is not just an experimental tool but a versatile therapeutic agent. By coupling direct oncolysis with broad immune microenvironment remodeling, it addresses the core causes of treatment failure. Future clinical trials will likely explore these combination strategies to improve long-term outcomes for patients with refractory disease.
Unlike many human-derived viruses, BoHV-1 is nonpathogenic to humans. This means patients are unlikely to have pre-existing antiviral immunity that would neutralize the virus before it reaches the tumor site.
Yes, research shows that BoHV-1 works synergistically with bortezomib, lenalidomide, and daratumumab, potentially increasing the effectiveness of these standard treatments.
Monocytes are crucial for the virus's success. BoHV-1 shifts them from an immunosuppressive state to a pro-inflammatory (M1-like) state, which helps the immune system actively attack the cancer.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
Raimondi V et al. Oncolytic bovine herpesvirus type 1 induces immune microenvironment remodeling and enhances treatment responses in multiple myeloma. Haematologica. 2026 Mar 26. doi: 10.3324/haematol.2025.289317. PMID: 41885031.
Raimondi V, Vescovini R, Dessena M, Donofrio G, Storti P, Giuliani N. Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients. Front Immunol. 2024 Oct 30;15:1483806. doi: 10.3389/fimmu.2024.1483806.
Thorne SH. Potential of oncolytic viruses in the treatment of multiple myeloma. Mol Ther. 2016;24(6):1021-1022. doi:10.1038/mt.2016.66.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Research highlights BoHV-1 as a potent oncolytic agent that kills myeloma cells and reverses immunosuppression in the bone marrow microenvironment....
4 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
